TIDES US 2023 Presentation: Engineered Enzymes to Overcome Challenges of Nucleic Acid Therapeutics

Ribonucleic acid as a therapeutic modality has gained tremendous traction in recent years; however, large-scale production faces complex challenges in nucleic acids quality and quantity, as well as overall economics. Targeting the growing number of mRNA vaccines in the marketplace and siRNA/ASO candidates advancing in clinical studies, we will share how engineered enzymes can overcome these difficulties to achieve scalable and sustainable manufacturing.